Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

An Independent US FDA: Gottlieb Supports Position, But Is Pessimistic About Prospects

Executive Summary

In an interview with the Pink Sheet, Scott Gottlieb agrees with other ex-commissioners that there are benefits to an independent agency, but he thinks political forces would prevent it from ever happening.

You may also be interested in...



How Can FDA Avoid Political Interference? More Independence, Fewer Appointees, GAO Says

Former agency heads and outside experts suggest structural reforms in interviews with GAO. Report notes FDA had 10 political appointees in 2020 versus 5 in 2016 and 3 in 2022. House Select Subcommittee on the Coronavirus Crisis describes Trump Administration actions against FDA in its final report.

Ex-Commissioners See Mostly Positives In Public View Of US FDA After COVID

Three of the US FDA’s former leaders believe the agency is coming through COVID with its reputation intact. They still support making the agency independent of the broader Health & Human Services Department, but the urgency may be gone.

Time For Independent US FDA? COVID Political Pressure Reignites Debate

The political spotlight on the FDA during the coronavirus pandemic has renewed long-standing debate as to whether it should be made an independent, Cabinet-level federal agency and freed from direct HHS oversight.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel